Bengaluru, April 12, 2023: As part of the development of its diagnostics network, leading global pharmaceutical company Lupin Limited (Lupin) today announced the opening of a brand-new, cutting-edge Regional Reference Laboratory in Bengaluru, Karnataka. In Lupin Diagnostics’ effort to offer accessible and reasonably priced diagnostics and preventive healthcare services across India, the new laboratory represents a significant advancement. The company’s current network of 25 laboratories and more than 410 collection centers across India is supplemented by the Regional Reference Laboratory.
Lupin Diagnostics is able to provide patients and customers in Bengaluru and surrounding cities with high-quality and dependable diagnostic services thanks to the new laboratory’s cutting-edge technology and workforce of highly qualified clinical professionals. The laboratory provides a wide range of diagnostic services, including routine biochemistry, molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, histopathology, immunology, and more, in addition to normal and specialized tests. Lupin Diagnostics uses cutting-edge automation and simplified procedures to give extremely accurate test results, enabling clients to make knowledgeable health decisions.
According to Ravindra Kumar, CEO of Lupin Diagnostics, “ensuring that high-quality diagnostics are available and affordable for everyone in India is at the core of our mission.” “A precise diagnosis is essential for the efficient management of diseases, and we are dedicated to offering our patients dependable, high-quality diagnostic services. Informed judgments about treatment options may be made by patients and clinicians thanks to our state-of-the-art technology and individualized smart reports, he continued.
Doctors, patients, and consumers can rely on Lupin Diagnostics for an unmatched selection of diagnostic services. Two of the company’s laboratories have already received NABL accreditation, demonstrating its constant dedication to quality and precision. This achievement strengthens Lupin Diagnostics’ position as a reputable leader in the healthcare sector and demonstrates the company’s commitment to excellence in all that it does.
More About Lupin
An international pharmaceutical firm with a focus on innovation, Lupin is based in Mumbai, India. The company creates and promotes a wide variety of branded and generic formulations, biotechnology goods, and APIs in more than 100 markets throughout the Americas, Europe, the Middle East, India, and South Africa.
The company has a strong presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health sectors and holds a leadership position in the cardiovascular, anti-diabetic, and respiratory segments. By prescriptions, Lupin ranks as the third-largest pharmaceutical firm in the United States. In FY22, the company spent 8.7% of its revenue on research & development. With 15 production facilities, 7 research facilities, and over 20,000 employees worldwide, Lupin has received regular recognition as a “Great Place to Work” in the biotechnology and pharmaceuticals industry.
More About Lupin Diagnostics
A fully owned subsidiary of Lupin Limited is Lupin Diagnostics Limited. The organization, which was established in December 2021 and has its headquarters in Mumbai, India, offers a wide range of diagnostic services to consumers, patients, and healthcare professionals. The business started off by building a cutting-edge 45,000 square foot National Reference Laboratory in Navi Mumbai with top-notch tools, qualified technicians assisting expert doctors, and strict quality control procedures.
Pathology offers more than 2,500 tests, both common and sophisticated (including molecular diagnostics, cytology, microbiology, serology, hematology, histopathology, immunology, and common biochemistry).
Currently, there are 25 labs, 410+ exclusive collection centers (LupiMitra), and more than 1200 pick-up stations in the company’s network.
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here
For more Pharma related updates Click here